Gastric Cancer Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Gastric Cancer Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Gastric Cancer Therapy Market is expected to register a CAGR of 15.8% during the forecast period (2022 - 2027).

The COVID-19 pandemic has affected the healthcare systems globally and also had a significant impact on the gastric cancer therapy market. For instance, as per an article published by the Nature Public Health Emergency Collection, in July 2021, titled “Impact of COVID-19 on gastric cancer treatment in Japanese high-volume centers: a JCOG stomach cancer study group survey”, it has been observed that the number of gastrectomies was almost 80% lower in 2020 than it was during the same period the year before, and hospitals in Tokyo suffered significantly from a 50% drop in this number. Thus, the decrease in the number of gastric cancer treatments is expected to have a significant impact on the studied market during the pandemic. Additionally, as per an article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types including gastric cancer. However, with the releasing COVID-19 restrictions the treatment and services are resuming which is expected to increase the hospital visits which in turn is anticipated to fuel the market growth over the forecast period.

Certain factors that are propelling the market growth are the growing burden of gastric cancer and the introduction of novel therapies for metastatic cancer. For instance, according to the 2022 statistics published by the American Cancer Society, about 26,380 new cases of stomach cancer (15,900 in men and 10,480 in women) are estimated to be diagnosed in the United States in 2022. In addition, according to an article published by the American Society of Clinical Oncology Journal, in July 2020, titled "Cancer Statistics, 2020: Report from National Cancer Registry Programme, India", it has been found that 50.8% of patients were diagnosed at the locally advanced stage of stomach cancer in India. Thus, the rising burden of stomach cancer among the population is expected to rise the demand for effective treatment and therapies, which in turn is anticipated to fuel the market growth.

Furthermore, the rising company’s focus in developing novel drugs and therapies for treating gastric cancer coupled with increasing product launches are all expected to boost the market growth over the forecast period. For instance, in November 2021, Natco Pharma launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer. Also, in April 2020, Samsung Bioepis launched ONTRUZANT a biosimilar of the reference biologic medicine HERCEPTIN, for the treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in the United States.

However, the high cost of cancer therapy and the side effects of drugs are likely to restrain the market growth over the forecast period.

Key Market TrendsTargeted Segment is Expected to Hold a Major Market Share in the Gastric Cancer Therapy Market

Targeted therapy is a treatment used for cancer, in which the drugs work by targeting the specific genes or proteins that are present in the cancer cells. There are several types of targeted therapies for cancers, such as hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, signal transduction inhibitors, and many other therapies.

Some of the targeted therapy drugs that are used to treat gastric cancer are ramucirumab, Bevacizumab, apatinib, sunitinib, trastuzumab, pertuzumab, lapatinib, and cetuximab. The segment is expected to witness significant growth over the forecast period owing to the factors such as the rising prevalence of gastric cancer among the population, increasing company activities in developing targeted therapies as well as growing research studies related to targeted drugs and therapies. For instance, according to an article published by the Lancet Summit Sex and Gender in rheumatology, in May 2022, titled “The current and future incidence and mortality of gastric cancer in 185 countries, 2020 – 40: A population-based modeling study”, the highest incidence of gastric cancer was observed in Eastern Asia for both males and females (32.5 and 13.2, per 1,00,000, respectively). In addition, as per the same source, the incidence rate of gastric cancer in males residing in Japan was 48.1 per 1,00,000, 47.2 in Mongolia, and 39.7 in Korea. Thus, the rising burden of gastric cancer among the population is expected to increase the demand for effective gastric cancer therapy and drugs, which is anticipated to increase the segment growth over the forecast period.

Furthermore, the rising product launches and approvals are expected to increase segment growth. For instance, in November 2021, the Japan Pharmaceuticals and Medical Devices Agency (PMDA) approved Merck’s KEYTRUDA as the first-line treatment for patients with radically unresectable, advanced, or recurrent esophageal carcinoma in combination with chemotherapy (5-fluorouracil [5-FU] plus cisplatin). Also, in April 2021, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin).

Therefore, due to the aforementioned factors, the studied market is expected to increase over the forecast period.

North America Dominates the Market and Expected to do the Same during the Forecast Period

North America is expected to dominate the gastric cancer therapy market over the forecast period owing to the factors such as the increasing prevalence of gastric cancer, rising adoption of targeted cancer therapy, and the availability of advanced technology in cancer research and treatment centers. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were estimated to develop gastric cancer in 2021. Also, according to the GLOBOCAN 2020 fact sheet, 29 772 new gastric cancer cases (18 175 males and 11 597 females) were reported in North America in 2020. In addition, as per the same source, 8,804 new cases of gastric cancer were reported in Mexico, in 2020. Thus, the increasing number of gastric cancer cases in the region is expected to rise the demand for effective therapies for treating patients with gastric cancer which in turn is anticipated to fuel the market growth over the forecast period.

Furthermore, the rising company activities in conducting clinical trials for developing effective drugs for patients suffering from gastric cancer as well as increasing product launches and approvals in the region are expected to fuel the market growth. For instance, in April 2021, the United States Food and Drug Administration approved Bristol Myers Squibb’s Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Also, in January 2021, the United States Food and Drug Administration approved Enhertu for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Therefore, due to the aforementioned factors, the studied market is expected to increase over the forecast period.

Competitive Landscape

The Gastric Cancer Therapy Market is competitive and consists of a few major players. In terms of shares, a few of the major players are currently dominating the market. Some of the major players in the market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Pfizer, Merck & Co. Inc., and Celltrion Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.